

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (CURRENTLY AMENDED) A method of ~~inhibiting~~ treating thrombotic conditions in blood in a subject in need thereof comprising administering to the subject an inhibitor of *syk* kinase and a pharmaceutically acceptable carrier.
2. (ORIGINAL) The method of claim 1, wherein the thrombotic condition is selected from the group consisting of thrombus formation, venous thromboembolism, pulmonary embolism, deep vein thrombosis, cardiogenic thromboembolism, thromboembolic stroke, and unstable angina.
3. (CANCEL)
4. (CANCEL)
5. (CANCEL)
6. (CANCEL)
7. (CURRENTLY AMENDED) The method of claim 1, wherein one adds A ~~method for inhibiting formation of blood platelet aggregates in blood comprising~~ adding to blood a therapeutically effective amount of an inhibitor of *syk* kinase to inhibit formation of blood platelet aggregates.
8. (CANCEL)
9. (ORIGINAL) A method of identifying a compound useful in the treatment of a thrombotic condition, comprising screening a library of candidate

compounds to identify those compounds which sustain constitutive eNOS activity during platelet aggregation.

10. (CANCEL)

11. (CANCEL)

12. (CANCEL)

13. (CANCEL)

14. (CURRENTLY AMENDED) [[A]] The method of claim 9, further identifying a compound useful in the treatment of a thrombotic condition, comprising screening to see if the compound also inhibits calpain a library of candidate compounds to identify those compounds which inhibit calpain and sustain constitutive eNOS activity during platelet aggregation.

15. (CANCEL)

16. (CANCEL)

17. (CANCEL)

18. (CANCEL)

19. (CURRENTLY AMENDED) [[A]] The method of claim 9, further comprising screening to see if the compound also inhibits GPIIb/IIIa identifying a compound useful in the treatment of thrombosis, comprising screening a library of candidate compounds to identify those compounds which inhibit GPIIb/IIIa and sustain constitutive eNOS activity during platelet aggregation.

20. (CANCEL)

21. (CANCEL)

22. (CANCEL)

23. (CANCEL)

24. (ORIGINAL) A method of promoting fibrinolysis in a subject in need thereof comprising administering to the subject a compound selected from the group consisting of an inhibitor of *syk* kinase and an inhibitor of calpain, and a pharmaceutically acceptable carrier.

25. (ORIGINAL) The method of claim 24 wherein the compound is an inhibitor of *syk* kinase.

26. (ORIGINAL) The method of claim 24 wherein the compound is an inhibitor of calpain.

27. (ORIGINAL) A kit for promoting fibrinolysis comprising the compound of claim 24 and a pharmaceutically acceptable carrier.